CDKN2A and neoplasm: Despite these insights, none of the 16 studies included molecular or epigenetic tumor profiling, such as TERT promoter mutations, CDKN2A/B deletions, or methylation subclasses, which are increasingly shown to correlate with prognosis and RT responsiveness.